BTIF downgraded Verastem (NASDAQ:VSTM) to “neutral” from “buy” and removed its previous price target of $8 after the company announced that president and CEO, Robert Forrester, was stepping down. The stock closed at $1...

Alliance Global Partners launched coverage of Precipio (NASDAQ:PRPO) with a “buy” rating and price target of $6.30. The stock closed at $3.12 on June 19.

Ladenburg Thalmann initiated coverage of Armata Pharmaceuticals (NYSE American:ARMP) with a “buy” rating and price target of $9. The stock closed at $2.86 on June 18.

Janney Montgomery Scott launched coverage of Anavex Life Science (NASDAQ:AVXL) with a “buy” rating and fair value estimate of $10. The stock closed at $3.14 on June 17.

Janney Montgomery Scott launched coverage of Neurotrope (NASDAQ:NTRP) with a “buy” rating and fair value estimate of $14. The stock closed at $6.36 on June 17.

SVB Leerink raised its price target for Provention Bio (NASDAQ:PRVB) to $17 from $5.50, following positive At-Risk trial results presented at the American Diabetes Association meeting last week. The stock closed at $11...

Roth Capital Partners initiated coverage of Translate Bio (NASDAQ:TBIO) with a “buy” rating and price target of $25. The stock closed at $10.08 on June 17.

H.C. Wainwright upgraded ReWalk Robotics (NASDAQ:RWLK) to “buy” from “neutral” and raised its price target to $9 from $4, citing several key milestones in the past few months. The stock closed at $5.21 on June 14.

Landenburg Thalmann downgraded Savara (NASDAQ:SVRA) to “neutral” from “buy” and slashed its price target to $3 from $21 after lead asset, Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage...

H.C. Wainwright slashed its price target for Tetraphase Pharmaceuticals (NASDAQ:TTPH) to $1.50 from $7 after the company unveiled a sweeping corporate reorganization. The stock closed at 74 cents on June 12.

BTIG initiated coverage of Misonix (NASDAQ:MSON) with a “buy” rating and $29 price target. The stock closed at $23.96 on June 11.

Ladenburg Thalmann raised its price target for Achieve Life Sciences (NASDAQ:ACHV) to $20 from $12 after the company reported statistically significant top-line results from its Phase 2 trial ORCA-1, which enrolled 254...

Roth Capital Partners initiated coverage of CRISPR Therapeutics PLC (NASDAQ:CRSP) with a “buy” rating and $50 price target. The stock closed at $44.38, up $1.50, on June 10.

H.C. Wainwright upgraded Sesen Bio (NASDAQ:SESN) to “buy” from “neutral” and raised its price target to $3 from $1 after the company had a successful Type B pre-biologics license application (BLA) meeting with FDA for...

Roth Capital Partners launched coverage of Intellia Therapeutics (NASDAQ:NTLA) with a “neutral” rating and $16 price target, saying the stock is fully valued ahead of first-in-human studies. The stock closed at $14.36...

SVB Leerink downgraded German drug maker InflaRx (NASDAQ:IFRX) to “market perform” from “outperform” and slashed its price target to $4 from $67 after its lead drug failed to benefit patients with a debilitating skin...

SVB Leerink launched coverage of Trevi Therapeutics (NASDAQ:TRVI) with an “outperform” rating and $14 price target. The stock closed at $9.99 on May 31.

SVB Leerink initiated coverage of Axcella Health (NASDAQ:AXLA) with an “outperform” rating and a $21 price target. The stock closed at $14.27 on May 31.

Roth Capital Partners launched coverage of Atara Biotherapeutics (NASDAQ:ATRA) with a “buy” rating and price target of $30. The stock closed at $23.30 on May 29.

Roth Capital Partners initiated coverage of Marker Therapeutics (NASDAQ:MRKR) with a “buy” rating and $10 price target. The stock closed at $5.91 on May 29.

Roth Capital Partners initiated coverage of Forty Seven (NASDAQ:FTSV) with a “buy” rating and $28 price target. The stock closed at $12.49, up 34 cents, on May 28.

Roth Capital Partners launched coverage of Five Prime Therapeutics (NASDAQ:FPRX) with a “neutral” rating and $10 price target. The stock closed at $8.73, down 32 cents, on May 28.